135 related articles for article (PubMed ID: 37545183)
21. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
22. Tumor Microenvironment Modulates Invadopodia Activity of Non-Selected and Acid-Selected Pancreatic Cancer Cells and Its Sensitivity to Gemcitabine and C18-Gemcitabine.
Carvalho TMA; Audero MM; Greco MR; Ardone M; Maggi T; Mallamaci R; Rolando B; Arpicco S; Ruffinatti FA; Pla AF; Prevarskaya N; Koltai T; Reshkin SJ; Cardone RA
Cells; 2024 Apr; 13(9):. PubMed ID: 38727266
[TBL] [Abstract][Full Text] [Related]
23. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.
Fujiwara-Tani R; Sasaki T; Takagi T; Mori S; Kishi S; Nishiguchi Y; Ohmori H; Fujii K; Kuniyasu H
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887170
[TBL] [Abstract][Full Text] [Related]
25. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
26. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
27. IFN‑γ induces apoptosis in gemcitabine‑resistant pancreatic cancer cells.
Kong X; Cheng D; Xu X; Zhang Y; Li X; Pan W
Mol Med Rep; 2024 May; 29(5):. PubMed ID: 38488034
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
29. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
30. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki M; Abe Y; Itoi T; Serizawa H; Nagao T; Shimazu M; Aoki T
Oncol Rep; 2011 Dec; 26(6):1399-406. PubMed ID: 21922147
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin.
Zhao X; Gao S; Ren H; Sun W; Zhang H; Sun J; Yang S; Hao J
Cancer Res; 2014 May; 74(9):2455-64. PubMed ID: 24599125
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancreatic ductal adenocarcinoma.
Tanaka T; Li TS; Urata Y; Goto S; Ono Y; Kawakatsu M; Matsushima H; Hirabaru M; Adachi T; Kitasato A; Takatsuki M; Kuroki T; Eguchi S
J Gastroenterol; 2015 Sep; 50(9):975-83. PubMed ID: 25542265
[TBL] [Abstract][Full Text] [Related]
34. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
35. Glycolysis and tumor progression promoted by the m
Yang K; Zhong Z; Zou J; Liao JY; Chen S; Zhou S; Zhao Y; Li J; Yin D; Huang K; Li Y
Cancer Lett; 2024 May; 590():216840. PubMed ID: 38604311
[TBL] [Abstract][Full Text] [Related]
36. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
37. A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.
Kato A; Ng S; Thangasamy A; Han H; Zhou W; Raeppel S; Fallon M; Guha S; Ammanamanchi S
Mol Carcinog; 2021 Nov; 60(11):734-745. PubMed ID: 34347914
[TBL] [Abstract][Full Text] [Related]
38. PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.
Ma J; Weng L; Jia Y; Liu B; Wu S; Xue L; Yin X; Mao A; Wang Z; Shang M
J Cell Mol Med; 2020 Mar; 24(5):2917-2930. PubMed ID: 31989778
[TBL] [Abstract][Full Text] [Related]
39. FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p/WNT5A/WNT pathway in PDAC.
Lu J; Yang Y; Liu X; Chen X; Song W; Liu Z
Cell Death Dis; 2023 Nov; 14(11):713. PubMed ID: 37914721
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
